The J.P. Morgan (JPM) Healthcare Conference kicks off next week, one of the largest and most important annual healthcare conferences of the year. That makes this the perfect time to take a look at a stock in the biotechnology sector which was beaten down last year, but looks ready to emerge like a phoenix from the ashes in 2024.
One biotechnology stock that had a rocky year in 2023, but looks like it’s already bottomed and is headed higher is Biomarin Pharmaceuticals (BMRN). While the stock was moving lower last year, mainly due to the pull of the industry it was in, Biomarin was busy getting approval internationally for several drugs which have started hitting the bottom line.
